First-line hydroxyurea may be effective in polycythemia vera, essential thrombocytopenia

February 2011
Hem/Onc Today;2/25/2011, Vol. 12 Issue 4, p8
The article provides information on research conducted in Barcelona, Spain which found that first-line hydroxyurea may be efficient in treating essential thrombocytopenia and polycythemia vera.


Related Articles

  • Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia. Albizua, Enriqueta; Gallardo, Miguel; Barrio, Santiago; Rapado, Inmaculada; Jimenez, Ana; Ayala, Rosa; Rueda, Daniel; Sanchez-Espiridion, Beatriz; Puigdecanet, Eulalia; Espinet, Blanca; Florensa, Lourdes; Besses, Carles; Martinez-Lopez, Joaquin // Annals of Hematology;Aug2011, Vol. 90 Issue 8, p939 

    This study investigates the differential gene expression profile of JAK2-positive myeloproliferative neoplasm (MPN) patients, with and without response to hydroxyurea (HU) treatment. Twenty-one polycythemia vera, 28 essential thrombocythemia, eight secondary erythrocytosis, and 30 controls were...

  • Anagrelide noninferiorto hydroxyurea in essential thrombocythemia.  // Hem/Onc Today;5/10/2013, Vol. 14 Issue 9, p16 

    The article provides information on a study which assessed the association of anagrelide with hydroxyurea and thrombocythemia.

  • Hydroxycarbamide.  // Reactions Weekly;03/23/2013, Issue 1445, p23 

    The article presents a case study of longitudinal melanonychia in a 72-year-old woman developed while undergoing treatment with hydroxycarbamide for thrombocythaemia.

  • Homoharringtonine is an effective therapy for patients with polycythemia vera or essential thrombocythemia who have failed or were intolerant to hydroxycarbamide or interferon-α therapy. Li, Yufeng; Zhu, Jiabin; Ding, Banghe // International Journal of Clinical Oncology;Oct2013, Vol. 18 Issue 5, p922 

    Background: At present, the treatment of polycythemia vera (PV) and essential thrombocythemia (ET) is still largely supportive and symptomatic. Homoharringtonine (HHT), a valid drug for treating chronic myelogenous leukemia, has shown some effect on leukemic stem cells. The aim of this study was...

  • BY THE NUMBERS.  // Hem/Onc Today;7/25/2014, Vol. 15 Issue 14, p1 

    The article presents a chart showing Ruxolitinib response to hematocrit, spleen volume in hydroxyurea-resistant/intolerant polycythemia vera and complete hematologic response.

  • Update in the myeloproliferative neoplasms. Harrison, Claire N; McMullin, Mary F // Clinical Medicine;2014 Supplement, Vol. 14, ps66 

    The differential diagnosis of haematological abnormalities, such as leucocytosis, erythocytosis, thrombocytosis or indeed anaemia, is wide and disarming. Here we report on significant updates in the differential diagnosis of erythrocyosis and thrombocytosis presenting a simplified schema for the...

  • Hydroxycarbamide: Multiple myeloma in an elderly patient: case report.  // Reactions Weekly;Dec2013, Issue 1481, p22 

    The article presents a case study of a 66-year-old man who experienced multiple myeloma while receiving hydroxycarbamide for essential thrombocythemia.

  • Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Alvarez-Larrán, Alberto; Martínez-Avilés, Luz; Hernández-Boluda, Juan; Ferrer-Marín, Francisca; Antelo, María; Burgaleta, Carmen; Mata, M.; Xicoy, Blanca; Martínez-Trillos, Alejandra; Gómez-Casares, M.; Durán, M.; Marcote, Bárbara; Ancochea, Agueda; Senín, Alicia; Angona, Anna; Gómez, Montse; Vicente, Vicente; Cervantes, Francisco; Bellosillo, Beatriz; Besses, Carles // Annals of Hematology;Dec2014, Vol. 93 Issue 12, p2037 

    Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited. Busulfan is effective as first-line therapy, but there is scarce information on this drug as second-line treatment. The efficacy of busulfan in...

  • Ruxolitinib shows promise in advanced polycythemia vera.  // Hem/Onc Today;1/10/2014, Vol. 15 Issue 1, p4 

    The article reports that according to results of a phase two study on ruxolitinib, Jakafi by Incyte Pharmaceuticals, ruxolitinib was found to have induced durable response and appeared to be well tolerated by patients with polycythemia vera who were refractory or intolerant to hydroxyurea.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics